TEVIMBRA’s Rising Impact - BeiGene Expands PD-1 Indication

added blog Health

2025-08-18 14:18:12 -

BeiGene’s PD-1 inhibitor, TEVIMBRA, continues to gain momentum in the oncology landscape with a newly secured indication, reinforcing its position in the competitive esophageal squamous cell carcinoma market. The recent approval of TEVIMBRA in the UK highlights BeiGene’s expanding influence beyond Asia, solidifying the drug as a strong contender against established therapies. What...

0 Comments 0 Shares 15 Views 0 Reviews